Dayvigo vs Quviviq

How they're similar

The two drugs are closely related in class and design.

• Same mechanism. Both block the OX1 and OX2 orexin receptors. Orexin is a wake-promoting neuropeptide, and blocking it lets sleep signals take over.
• Same broad indication. Both are FDA-approved for adults with insomnia, specifically for difficulty with sleep onset (falling asleep) and sleep maintenance (staying asleep).
• Similar modest effectiveness. Trials show both shorten time to sleep by roughly 10 to 20 minutes and increase total sleep time by 20 to 40 minutes compared with placebo. That's real but not dramatic.
• Both are Schedule IV controlled substances, reflecting some abuse potential. That risk is considered lower than benzodiazepines or z-drugs (zolpidem, eszopiclone), but not zero.
• Both are less likely to cause the rebound insomnia and tolerance that older sleep medications can produce. That's part of the class advantage.
• Both are metabolized primarily by CYP3A4. Strong inhibitors of CYP3A4 (like ketoconazole, some antifungals, some HIV medications) raise levels significantly. Moderate inhibitors (diltiazem, verapamil, some macrolides) also matter.
• Both should be taken about 30 minutes before bedtime, at least 7 hours before intended wake-up. Taking either drug with a large meal delays absorption and slows onset.
• Both are contraindicated in narcolepsy. Because narcolepsy involves loss of orexin already, blocking it further makes things worse.
• Both can cause rare but distinctive orexin-class side effects: sleep paralysis, hypnagogic or hypnopompic hallucinations (vivid dreamlike experiences at sleep onset or waking), and rarely cataplexy-like symptoms (sudden brief muscle weakness).
• Both are relatively new. Lemborexant was FDA-approved in 2019, daridorexant in 2022.
• Both are brand-name only, expensive, and often require prior authorization.

The class is genuinely different from benzodiazepines and z-drugs. It's worth stepping back for that context. If someone has been on zolpidem or lorazepam for sleep and worries about the long-term effects on cognition, memory, and dependence, DORAs offer an alternative that at least in principle avoids some of those problems. The tradeoff is that they're expensive, sometimes less potent for severe insomnia, and don't have as long a real-world track record.

How they differ

The differences are mostly in pharmacokinetics.

The half-life difference drives most of the practical distinction. Lemborexant sticks around in the body for roughly 17 to 19 hours. That helps with staying asleep through the night, but it also means more of the drug is still present in the morning. For some people that shows up as grogginess, delayed reaction time, or a subtle heaviness in the first few hours after waking. The 10 mg dose is more likely to produce this than the 5 mg dose.

Daridorexant was designed with next-day effects specifically in mind. Its half-life of about 8 hours means it's mostly cleared by the time someone wakes up. In studies, daridorexant showed less impairment on next-day driving simulation tests and cognitive tests than lemborexant. That said, next-day effects still happen for some people, especially at the 50 mg dose or when sleep is cut short.

Dosing is straightforward for both. Lemborexant starts at 5 mg and can go up to 10 mg based on response and tolerability. Daridorexant is offered as 25 mg or 50 mg, and the 50 mg dose is more effective in trials, though the 25 mg dose has fewer next-day effects for those sensitive to that.

Both need to be taken about 30 minutes before bedtime, and both should be taken with at least 7 hours available for sleep. Taking either drug and then getting up within a few hours is where next-day impairment problems most often show up.

Food interactions matter. Both drugs are delayed and reduced in effect if taken with a large or fatty meal. Ideally they're taken on an empty stomach or a light snack, with at least a few hours between dinner and the dose.

Side effect tendencies

Side effect profiles are similar between the two.

Next-day sedation is the most common. It shows up more often with higher doses and with lemborexant more than daridorexant. For most people it eases after the first several nights as the body adjusts. If it persists, lowering the dose usually helps.

Headache is common, usually mild.

Abnormal or vivid dreams happen with both, part of the class effect. Some people find their dreams more intense or memorable. For most this is neutral or interesting. For some it's distressing and a reason to switch or stop.

Sleep paralysis is a rare but documented side effect. It's the temporary inability to move at the transition between sleep and waking. It usually lasts seconds to a minute or two and resolves on its own. It can be frightening the first time. It's uncommon but worth knowing about.

Hypnagogic or hypnopompic hallucinations are rare. These are dreamlike sensory experiences when falling asleep or waking, sometimes visual, sometimes auditory. Again, uncommon but distinctive to this class.

Cataplexy-like symptoms are rare. These are brief episodes of muscle weakness, sometimes triggered by strong emotion. This is why narcolepsy patients shouldn't take these drugs. When it happens in non-narcolepsy patients, it's usually brief and mild but a reason to stop the medication.

Complex sleep behaviors (sleepwalking, sleep-eating, sleep-driving) have been reported rarely with DORAs, similar to but likely less common than with zolpidem. Any evidence of these behaviors means stopping the drug.

Depression and suicidality have been reported in trials. Both drugs carry a warning about worsening of depression and suicidal thinking. It's uncommon but worth screening for.

Alcohol interaction is a real concern. Combining either drug with alcohol worsens sedation and next-day effects. Avoiding alcohol on nights the medication is taken is the sensible approach.

What tips the choice

The practical factors usually decide.

If next-day residual effects are the top concern, daridorexant tends to have the edge. Its shorter half-life was engineered to reduce morning grogginess.

If sleep maintenance is the main problem, either can work, and lemborexant's longer duration may help some people stay asleep through the second half of the night.

Insurance coverage often decides. Both are brand-name, both are expensive, and both often require prior authorization. Which one a plan prefers can change year to year.

Age matters. Older adults are more sensitive to next-day effects and to falls at night. Daridorexant may be a gentler starting choice in older patients. Lower doses of either are reasonable in this group.

Prior response matters. If someone tried one and had persistent morning grogginess, switching to the other (or lowering the dose) can help.

Interactions with other medications matter. Anyone on strong CYP3A4 inhibitors like some antifungals or HIV medications needs careful dose adjustment or a different sleep medication altogether.

Neither drug replaces addressing the causes of insomnia. Sleep hygiene, cognitive behavioral therapy for insomnia (CBT-I), evaluation for sleep apnea, and management of anxiety or depression matter regardless of which pill someone takes. CBT-I in particular has better long-term outcomes than any medication for chronic insomnia.

Both are meant for short-term or intermittent use in many cases, though they can be used longer term. The evidence for long-term daily use isn't as extensive as for older medications, but so far the safety looks reasonable.

Common questions

Are these better than Ambien or Lunesta? They're different, and the honest answer depends on what matters most. Compared to zolpidem (Ambien) and eszopiclone (Lunesta), DORAs are less likely to cause dependence, tolerance, and the strange sleep behaviors zolpidem can produce. They may be slightly less potent for severe insomnia. Zolpidem tends to work faster to initiate sleep. DORAs preserve more normal sleep architecture. Cost is a big difference, since zolpidem is very cheap and DORAs are expensive.

Will I feel groggy in the morning? For most people at appropriate doses, morning grogginess is mild or absent. It's more common with lemborexant 10 mg than daridorexant 50 mg, and it's more likely when sleep is cut short. Giving yourself at least 7 hours in bed before the alarm is important with both drugs.

Are these safe for long-term use? Long-term data for both is still growing. Studies out to 12 months show reasonable safety without major tolerance or dose escalation problems. Longer than that, the data is limited but so far reassuring. That said, for chronic insomnia, CBT-I is the treatment with the strongest long-term evidence, and it's worth pursuing alongside or before medication.

Can I stop these suddenly? Rebound insomnia and withdrawal are less pronounced with DORAs than with benzodiazepines or z-drugs. Some people do notice a few nights of worse sleep after stopping, but severe withdrawal isn't typical. Still, if the drug has been used nightly for a long time, tapering under a prescriber's guidance is reasonable.

Do these interact with alcohol? Yes, and it matters. Alcohol worsens sedation and next-day effects from both drugs. It also worsens the sleep quality that either drug is meant to improve. Avoiding alcohol on nights the medication is taken is the safe practice.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes. This is not medical advice.

1. U.S. Food and Drug Administration. Lemborexant (Dayvigo) prescribing information.
2. U.S. Food and Drug Administration. Daridorexant (Quviviq) prescribing information.
3. American Academy of Sleep Medicine. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults.
4. MedlinePlus, U.S. National Library of Medicine.